• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.地高辛治疗监测：II. 表观分布容积的决定因素。
Br J Clin Pharmacol. 1977 Apr;4(2):223-7. doi: 10.1111/j.1365-2125.1977.tb00698.x.
2
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.监测地高辛治疗：I. 血浆浓度及组织反应的体外测定
Br J Clin Pharmacol. 1977 Apr;4(2):213-21. doi: 10.1111/j.1365-2125.1977.tb00697.x.
3
Digoxin in the elderly and in renal failure. Contribution of erythrocyte 86-rubidium uptake tests.老年人及肾衰竭患者中的地高辛。红细胞86铷摄取试验的作用。
Eur J Cardiol. 1981;12(5):285-96.
4
Proceedings: The influence of digoxin metabolites on 86Rb-uptake of human erythrocytes.论文集：地高辛代谢产物对人红细胞摄取⁸⁶Rb的影响。
Naunyn Schmiedebergs Arch Pharmacol. 1975;287 Suppl:R41.
5
In vivo cation transport during short-term and long-term digoxin therapy.短期和长期地高辛治疗期间的体内阳离子转运
Br J Clin Pharmacol. 1986 Jul;22(1):27-30. doi: 10.1111/j.1365-2125.1986.tb02875.x.
6
Factors influencing the inhibition by digoxin of 86 Rubidium uptake into human red cells.影响地高辛对铷86摄入人红细胞抑制作用的因素。
Med Lab Sci. 1979;36(4):339-52.
7
Erythrocyte cation transport and age: effects of digoxin and furosemide.红细胞阳离子转运与年龄：地高辛和呋塞米的影响
Clin Pharmacol Ther. 1983 Aug;34(2):159-63. doi: 10.1038/clpt.1983.146.
8
Quinidine-digoxin interaction: effect of quinidine on 86Rb-uptake of human erythrocytes.奎尼丁-地高辛相互作用：奎尼丁对人红细胞摄取⁸⁶Rb的影响
Klin Wochenschr. 1981 Jan 15;59(2):95-6. doi: 10.1007/BF01477289.
9
The influence of metabolites of digoxin and digitoxin on the 86Rb-uptake assay.地高辛和洋地黄毒苷的代谢产物对86Rb摄取试验的影响。
Eur J Clin Pharmacol. 1973 Jun;6(1):54-6. doi: 10.1007/BF00561801.
10
Study of the sensitivity of neonates to digoxin: contribution of erythrocyte 86rubidium uptake test.新生儿对地高辛敏感性的研究：红细胞86铷摄取试验的作用
Pediatr Pharmacol (New York). 1981;1(3):221-9.

引用本文的文献

1
Loading dose of digoxin in renal failure.肾衰竭患者地高辛的负荷剂量。
Br J Clin Pharmacol. 1980 Jun;9(6):593-7. doi: 10.1111/j.1365-2125.1980.tb01085.x.
2
Digoxin distribution between plasma and myocardium in hypoxic and non-hypoxic dogs.缺氧和非缺氧犬血浆与心肌之间的地高辛分布
Experientia. 1982 Jul 15;38(7):839-41. doi: 10.1007/BF01972304.
3
Clinical pharmacokinetics of digoxin 1980.地高辛的临床药代动力学 1980 年
Clin Pharmacokinet. 1980 Mar-Apr;5(2):137-49. doi: 10.2165/00003088-198005020-00002.
4
Indications for the measurement of plasma digoxin concentrations.血浆地高辛浓度测定的适应证。
Drugs. 1983 Sep;26(3):230-42. doi: 10.2165/00003495-198326030-00004.
5
Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.肾功能不全患者中强心苷类药物的临床药代动力学
Clin Pharmacokinet. 1983 Mar-Apr;8(2):155-78. doi: 10.2165/00003088-198308020-00003.
6
Erythrocyte Na+, K+-ATPase and serum digoxin concentrations.红细胞钠钾ATP酶和血清地高辛浓度
Eur J Clin Pharmacol. 1983;24(6):807-12. doi: 10.1007/BF00607092.
7
Serum digoxin concentrations in a representative digoxin-consuming adult population.具有代表性的服用地高辛的成年人群的血清地高辛浓度。
Eur J Clin Pharmacol. 1985;27(6):627-32. doi: 10.1007/BF00547039.
8
Physiological changes due to age. Implications for cardiovascular drug therapy.年龄引起的生理变化。对心血管药物治疗的影响。
Drugs Aging. 1991 Nov-Dec;1(6):467-76. doi: 10.2165/00002512-199101060-00006.
9
Age-related differences in digoxin toxicity and its treatment.地高辛毒性及其治疗的年龄相关差异。
Drug Saf. 1992 Mar-Apr;7(2):135-51. doi: 10.2165/00002018-199207020-00005.
10
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.监测地高辛治疗：I. 血浆浓度及组织反应的体外测定
Br J Clin Pharmacol. 1977 Apr;4(2):213-21. doi: 10.1111/j.1365-2125.1977.tb00697.x.

本文引用的文献

1
ENZYMATIC BASIS FOR ACTIVE TRANSPORT OF NA+ AND K+ ACROSS CELL MEMBRANE.钠离子和钾离子跨细胞膜主动运输的酶学基础
Physiol Rev. 1965 Jul;45:596-617. doi: 10.1152/physrev.1965.45.3.596.
2
Blood levels of drug at the equilibrium state after multiple dosing.多次给药后达到平衡状态时药物的血药浓度。
Nature. 1965 Sep 18;207(5003):1301-2. doi: 10.1038/2071301a0.
3
Digoxin metabolism in the elderly.老年人地高辛的代谢
Circulation. 1969 Apr;39(4):449-53. doi: 10.1161/01.cir.39.4.449.
4
Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay.采用放射免疫分析法测定治疗性和中毒性血清地高辛浓度。
N Engl J Med. 1969 Nov 27;281(22):1212-6. doi: 10.1056/NEJM196911272812203.
5
Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes.地高辛特异性抗体对人红细胞摄取和结合地高辛的影响。
J Clin Invest. 1973 Aug;52(8):1820-33. doi: 10.1172/JCI107364.
6
The bioavailability of other digoxin preparations compared with tablets.与片剂相比，其他地高辛制剂的生物利用度。
Postgrad Med J. 1974 Nov;50 Suppl 6:62-6.
7
The biological availability of very rapidly dissolving digoxin tablets.速溶地高辛片的生物利用度。
Postgrad Med J. 1974 Nov;50 Suppl 6:55-9.
8
Effect of age and cardiac glycosides on the activity of adenosine triphosphatase (ATPase) (EC 3.6.1.3) of red cell ghost membranes.年龄和强心苷对红细胞血影膜三磷酸腺苷酶（ATP酶）（EC 3.6.1.3）活性的影响。
Mech Ageing Dev. 1974 Nov-Dec;3(5-6):245-52. doi: 10.1016/0047-6374(74)90021-9.
9
Decreased ouabain-sensitive adenosine triphosphatase activity in the erythrocyte membrame of patients with chronic renal disease.慢性肾病患者红细胞膜中哇巴因敏感性三磷酸腺苷酶活性降低。
Clin Sci Mol Med. 1973 Dec;45(6):775-84. doi: 10.1042/cs0450775.
10
Induction of a ouabain-sensitive ATPase defect by uremic plasma.尿毒症血浆诱导哇巴因敏感的ATP酶缺陷
Trans Assoc Am Physicians. 1968;81:213-20.

地高辛治疗监测：II. 表观分布容积的决定因素。

Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.

作者信息

Aronson J K, Grahame-Smith D G

出版信息

Br J Clin Pharmacol. 1977 Apr;4(2):223-7. doi: 10.1111/j.1365-2125.1977.tb00698.x.

DOI:10.1111/j.1365-2125.1977.tb00698.x
PMID:861137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1429023/
Abstract

1 In eighteen subjects receiving digoxin therapy the apparent volume of distribution (Vd) of the drug has been calculated. 2 For each subject the sensitivity of the 86Rb transport mechanism of his pre-treatment erythrocytes to in vitro inhibition by digoxin has been measured (IC50). 3 The Vd of digoxin correlates both with the age of the patients and with the IC50 of their pre-treatment erythrocytes. 4 The implications of these findings are discussed in terms of the possible determinants of the Vd of digoxin. 5 Digoxin requirements may be predictable before therapy commences if IC50 measurements are performed.

摘要
  1. 在18名接受地高辛治疗的受试者中，已计算出该药物的表观分布容积（Vd）。2. 对每个受试者，已测量其治疗前红细胞的86Rb转运机制对体外地高辛抑制的敏感性（IC50）。3. 地高辛的Vd与患者年龄以及他们治疗前红细胞的IC50均相关。4. 根据地高辛Vd的可能决定因素讨论了这些发现的意义。5. 如果进行IC50测量，地高辛需求量在治疗开始前可能是可预测的。